Recent News

• 11.17.2025 - BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease
• 11.12.2025 - BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.12.2025 - BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.05.2025 - BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
• 11.05.2025 - BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
• 10.27.2025 - BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market
• 10.27.2025 - BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market
• 10.22.2025 - BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio
• 10.22.2025 - BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio
• 10.15.2025 - BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit

Recent Filings

• 11.12.2025 - 8-K Current report
• 11.12.2025 - EX-99.1 EX-99.1
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.09.2025 - D Notice of Exempt Offering of Securities
• 10.08.2025 - EX-99.1 EX-99.1
• 10.08.2025 - 8-K Current report
• 10.08.2025 - 424B5 Prospectus [Rule 424(b)(5)]